Neuropathic Pain Market was valued at USD 8.13 Bn in 2023 and is expected to reach USD 11.91 Bn by 2030, at a CAGR of 5.6 % during the forecast period.Neuropathic Pain Market Overview
Neuropathic pain is a type of chronic pain that occurs due to damage or dysfunction of the nervous system. Unlike nociceptive pain, which arises from tissue damage or inflammation, neuropathic pain originates from abnormal signaling within the nervous system itself. It manifest as shooting or burning sensations, tingling, numbness, or hypersensitivity to touch. Neuropathic pain result from various conditions, including nerve injuries, diseases such as diabetes or multiple sclerosis, infections, spinal cord injuries, or certain medications. The damaged nerves send incorrect signals to the brain, leading to the perception of pain even in the absence of a painful stimulus.To know about the Research Methodology :- Request Free Sample Report The neuropathic pain market has been evolving rapidly due to several factors, including the increasing prevalence of chronic pain conditions, advancements in treatment options, and growing awareness among healthcare professionals and patients. The neuropathic pain market has been witnessing steady growth, driven by the rising prevalence of neuropathic pain conditions worldwide. Conditions such as diabetic neuropathy, postherpetic neuralgia, neuropathic back pain, and trigeminal neuralgia contribute significantly to the market's expansion. According to MMR reports, the neuropathic pain market size is expected to continue growing over the forecast period, driven by the increasing elderly population, rising incidence of chronic diseases, and expanding treatment options.
Neuropathic Pain Market Dynamics
Rising Prevalence of Neuropathic Pain Conditions to boost Neuropathic Pain Market Growth The increasing prevalence of conditions associated with neuropathic pain significantly boost the Neuropathic Pain Market growth. Chronic diseases such as diabetes, autoimmune disorders, infections (e.g., herpes zoster), and neurological conditions (e.g., multiple sclerosis) are major contributors to neuropathic pain. As the global burden of these diseases continues to rise due to factors such as aging populations and lifestyle changes, the incidence of neuropathic pain is expected to increase, driving demand for effective treatments. Advances in pharmacological and non-pharmacological treatments for neuropathic pain have significantly impacted the market. Pharmaceutical innovations, including the development of novel analgesics, reformulations of existing drugs, and targeted therapies, have expanded treatment options for patients. Advancements in non-pharmacological interventions such as neurostimulation techniques, physical therapy modalities, and psychological interventions offer alternative approaches to pain management, further driving Neuropathic Pain market growth. There is a growing recognition of the importance of pain management, including neuropathic pain, as an essential aspect of healthcare. Healthcare providers, policymakers, and advocacy groups are increasingly emphasizing the need to address pain effectively and improve patients' quality of life. This focus on pain management has led to greater investment in research, education, and access to treatments, driving growth in the neuropathic pain market. The global demographic shift towards an aging population is a significant driver of the neuropathic pain market. Older adults are more susceptible to chronic diseases and neurological conditions associated with neuropathic pain, such as diabetes, peripheral neuropathy, and postherpetic neuralgia. As the elderly population continues to grow, particularly in developed countries, the prevalence of neuropathic pain is expected to rise, fueling demand for pain management solutions. Limited Efficacy of Current Treatments to limit Neuropathic Pain Market growth Despite advancements in treatment options, many patients with neuropathic pain continue to experience inadequate pain relief or adverse side effects from available therapies. The complex nature of neuropathic pain and the variability in individual patient responses pose challenges in achieving optimal treatment outcomes. This limitation underscores the need for more effective and personalized approaches to pain management. Developing novel treatments for neuropathic pain involves significant research and development (R&D) costs, as well as lengthy and rigorous regulatory approval processes, which is expected to boost the Neuropathic Pain Market growth. Pharmaceutical companies invest substantial resources in preclinical studies, clinical trials, and regulatory submissions to bring new therapies to market. Uncertainties associated with clinical trial outcomes and regulatory requirements add complexity and risk to the drug development process, leading to delays and increased costs. Many pharmacological treatments for neuropathic pain are associated with safety concerns and potential side effects, including gastrointestinal disturbances, sedation, cognitive impairment, and addiction. These adverse impact patient compliance, quality of life, and treatment outcomes, which is expected to limit the Neuropathic Pain Market growth. Healthcare providers must carefully balance the benefits and risks of medications when prescribing them for neuropathic pain, highlighting the need for safer and better-tolerated treatment options. The opioid epidemic, fueled by the overprescription and misuse of opioid analgesics, has led to heightened regulatory scrutiny and restrictions on opioid prescribing practices. While opioids provide effective pain relief for some patients with neuropathic pain, their potential for abuse, addiction, and overdose poses significant public health concerns. Regulatory agencies have implemented measures to curb opioid misuse, such as prescribing guidelines, prescription drug monitoring programs, and restrictions on opioid availability, which limit access to opioid-basedNeuropathic Pain Market Segment Analysis
Based on Drug Class, the market is segmented into Antidepressants, Anticonvulsant, Opioids, Capsaicin, and Others. Anticonvulsant segment dominated the market in 2023 and is expected to hold the largest Neuropathic Pain Market share over the forecast period. The anticonvulsant segment in the neuropathic pain industry is a category of medications primarily used for the treatment of seizures (epilepsy) but also widely prescribed for managing neuropathic pain. Anticonvulsants, also known as antiepileptic drugs (AEDs), exert their therapeutic effects by modulating neuronal excitability and neurotransmitter activity in the central nervous system. Anticonvulsants act on various molecular targets within the nervous system to stabilize neuronal membranes, inhibit excessive neuronal firing, and reduce the transmission of pain signals. Many anticonvulsants block voltage-gated sodium channels, which are responsible for propagating action potentials along neuronal axons. By inhibiting sodium channel activity, anticonvulsants reduce the influx of sodium ions into neurons, thereby dampening neuronal excitability and preventing the generation of abnormal electrical discharges, which significantly boosts the Neuropathic Pain Market growth.Based on Indication, the market is segmented into Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, and Others. Diabetic Neuropathy segment dominated the market in 2023 and is expected to hold the largest Neuropathic Pain Market share over the forecast period. Diabetic neuropathy is a specific segment within the broader neuropathic pain industry, focusing on neuropathic pain conditions that arise as a complication of diabetes mellitus. Diabetic neuropathy refers to nerve damage caused by prolonged exposure to high blood sugar levels (hyperglycemia) in individuals with diabetes. This nerve damage manifest in various parts of the body, leading to neuropathic pain symptoms and sensory disturbances. Diabetic neuropathy is a specific segment within the broader neuropathic pain market, focusing on neuropathic pain conditions that arise as a complication of diabetes mellitus. Diabetic neuropathy refers to nerve damage caused by prolonged exposure to high blood sugar levels (hyperglycemia) in individuals with diabetes. This nerve damage manifest in various parts of the body, leading to neuropathic pain symptoms and sensory disturbances. Diabetic neuropathy significantly impact patients' quality of life and functional status, leading to disability, decreased mobility, and impaired daily activities. There is a growing clinical need for effective treatments that alleviate neuropathic pain symptoms, improve sensory function, and prevent disease progression.
Neuropathic Pain Market Regional Insight
Increasing Prevalence of Neuropathic Pain Conditions to boost North America Neuropathic Pain Market growth North America has a significant burden of neuropathic pain conditions, including diabetic neuropathy, postherpetic neuralgia, neuropathic back pain, and trigeminal neuralgia. The region's aging population, rising incidence of chronic diseases such as diabetes and cancer, and lifestyle factors contribute to the increasing prevalence of neuropathic pain. As a result, there is a growing demand for effective pain management solutions, driving market growth. The North America neuropathic pain market benefits from continuous advancements in treatment options, including pharmacological and non-pharmacological interventions. Pharmaceutical innovations, such as the development of novel analgesics, reformulations of existing drugs, and targeted therapies, expand treatment options for patients with neuropathic pain. Advancements in non-pharmacological interventions, such as neurostimulation techniques, physical therapy modalities, and psychological interventions, offer alternative approaches to pain management, driving market growth. In March 2023, Confo Therapeutics, a company in the discovery of medicines targeting G-protein coupled receptors (GPCRs), announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) currently in Phase 1 clinical development, represents a non-opioid approach to treating neuropathic pain, a devastating condition caused by damage to the nerves outside of the brain and spinal cord, and potentially additional peripheral pain indications. Current treatment methods are often insufficiently effective and lead to serious side effects including addiction. Patients suffering from peripheral pain are therefore in urgent need of effective analgesics that are well-tolerated and do not impact quality of life.Neuropathic Pain Market Scope: Inquire before buying
Global Neuropathic Pain Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 8.13 Bn. Forecast Period 2024 to 2030 CAGR: 5.6% Market Size in 2030: US $ 11.91 Bn. Segments Covered: by Drug Class Antidepressants Anticonvulsant Opioids Capsaicin Others by Indication Diabetic Neuropathy Spinal Stenosis Chemotherapy-Induced Peripheral Neuropathy Others by Distribution Channel Hospital Pharmacies Drugs Stores and Retail Pharmacies Online Pharmacies Neuropathic Pain Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Leading Neuropathic Pain key Players include:
North America: 1. Pfizer Inc. - New York, United States 2. Eli Lilly and Company - Indianapolis, United States 3. Johnson & Johnson - New Brunswick, United States 4. Teva Pharmaceutical Industries Ltd. - Tel Aviv, Israel 5. Purdue Pharma - Stamford, United States 6. Endo Pharmaceuticals Inc. - Dublin, Ireland 7. AbbVie Inc. - North Chicago, United States 8. Mallinckrodt Pharmaceuticals - Staines-upon-Thames, United Kingdom 9. Biogen Inc. - Cambridge, United States Europe: 10. GlaxoSmithKline plc - Brentford, United Kingdom 11. Novartis AG - Basel, Switzerland 12. AstraZeneca plc - Cambridge, United Kingdom 13. Bayer AG - Leverkusen, Germany 14. Merck KGaA - Darmstadt, Germany 15. Boehringer Ingelheim - Ingelheim am Rhein, Germany 16. Sanofi - Paris, France 17. UCB S.A. - Brussels, Belgium 18. Ipsen Pharma - Paris, France 19. Grünenthal GmbH - Aachen, Germany Asia Pacific: 20. Takeda Pharmaceutical Company Limited - Tokyo, Japan 21. Eisai Co., Ltd. - Tokyo, Japan 22. Astellas Pharma Inc. - Tokyo, Japan 23. Otsuka Holdings Co., Ltd. - Tokyo, Japan 24. Mitsubishi Tanabe Pharma Corporation - Osaka, Japan Frequently Asked Questions: 1. What is neuropathic pain? Ans: Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. Unlike nociceptive pain, which arises from tissue damage or inflammation, neuropathic pain originates from abnormal signaling within the nervous system itself. 2. What conditions can cause neuropathic pain? Ans: Neuropathic pain result from various conditions, including nerve injuries, diseases such as diabetes or multiple sclerosis, infections, spinal cord injuries, or certain medications. 3. How is the neuropathic pain market evolving? Ans: The neuropathic pain market is experiencing steady growth due to increasing prevalence of chronic pain conditions, advancements in treatment options, and growing awareness among healthcare professionals and patients. 4. What are the key drivers of the neuropathic pain market? Ans: Key drivers include the rising prevalence of neuropathic pain conditions worldwide, advancements in treatment options, increasing elderly population, and expanding treatment options such as pharmacological and non-pharmacological interventions.
1. Neuropathic Pain Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Neuropathic Pain Market: Dynamics 2.1. Neuropathic Pain Market Trends by Region 2.1.1. North America Neuropathic Pain Market Trends 2.1.2. Europe Neuropathic Pain Market Trends 2.1.3. Asia Pacific Neuropathic Pain Market Trends 2.1.4. Middle East and Africa Neuropathic Pain Market Trends 2.1.5. South America Neuropathic Pain Market Trends 2.2. Neuropathic Pain Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Neuropathic Pain Market Drivers 2.2.1.2. North America Neuropathic Pain Market Restraints 2.2.1.3. North America Neuropathic Pain Market Opportunities 2.2.1.4. North America Neuropathic Pain Market Challenges 2.2.2. Europe 2.2.2.1. Europe Neuropathic Pain Market Drivers 2.2.2.2. Europe Neuropathic Pain Market Restraints 2.2.2.3. Europe Neuropathic Pain Market Opportunities 2.2.2.4. Europe Neuropathic Pain Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Neuropathic Pain Market Drivers 2.2.3.2. Asia Pacific Neuropathic Pain Market Restraints 2.2.3.3. Asia Pacific Neuropathic Pain Market Opportunities 2.2.3.4. Asia Pacific Neuropathic Pain Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Neuropathic Pain Market Drivers 2.2.4.2. Middle East and Africa Neuropathic Pain Market Restraints 2.2.4.3. Middle East and Africa Neuropathic Pain Market Opportunities 2.2.4.4. Middle East and Africa Neuropathic Pain Market Challenges 2.2.5. South America 2.2.5.1. South America Neuropathic Pain Market Drivers 2.2.5.2. South America Neuropathic Pain Market Restraints 2.2.5.3. South America Neuropathic Pain Market Opportunities 2.2.5.4. South America Neuropathic Pain Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Neuropathic Pain Industry 2.8. Analysis of Government Schemes and Initiatives For Neuropathic Pain Industry 2.9. Neuropathic Pain Market Trade Analysis 2.10. The Global Pandemic Impact on Neuropathic Pain Market 3. Neuropathic Pain Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 3.1.1. Antidepressants 3.1.2. Anticonvulsant 3.1.3. Opioids 3.1.4. Capsaicin 3.1.5. Others 3.2. Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 3.2.1. Diabetic Neuropathy 3.2.2. Spinal Stenosis 3.2.3. Chemotherapy-Induced Peripheral Neuropathy 3.2.4. Others 3.3. Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 3.3.1. Hospital Pharmacies 3.3.2. Drugs Stores and Retail Pharmacies 3.3.3. Online Pharmacies 3.4. Neuropathic Pain Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Neuropathic Pain Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 4.1.1. Antidepressants 4.1.2. Anticonvulsant 4.1.3. Opioids 4.1.4. Capsaicin 4.1.5. Others 4.2. North America Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 4.2.1. Diabetic Neuropathy 4.2.2. Spinal Stenosis 4.2.3. Chemotherapy-Induced Peripheral Neuropathy 4.2.4. Others 4.3. North America Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 4.3.1. Hospital Pharmacies 4.3.2. Drugs Stores and Retail Pharmacies 4.3.3. Online Pharmacies 4.4. North America Neuropathic Pain Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 4.4.1.1.1. Antidepressants 4.4.1.1.2. Anticonvulsant 4.4.1.1.3. Opioids 4.4.1.1.4. Capsaicin 4.4.1.1.5. Others 4.4.1.2. United States Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 4.4.1.2.1. Diabetic Neuropathy 4.4.1.2.2. Spinal Stenosis 4.4.1.2.3. Chemotherapy-Induced Peripheral Neuropathy 4.4.1.2.4. Others 4.4.1.3. United States Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.1.3.1. Hospital Pharmacies 4.4.1.3.2. Drugs Stores and Retail Pharmacies 4.4.1.3.3. Online Pharmacies 4.4.2. Canada 4.4.2.1. Canada Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 4.4.2.1.1. Antidepressants 4.4.2.1.2. Anticonvulsant 4.4.2.1.3. Opioids 4.4.2.1.4. Capsaicin 4.4.2.1.5. Others 4.4.2.2. Canada Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 4.4.2.2.1. Diabetic Neuropathy 4.4.2.2.2. Spinal Stenosis 4.4.2.2.3. Chemotherapy-Induced Peripheral Neuropathy 4.4.2.2.4. Others 4.4.2.3. Canada Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.2.3.1. Hospital Pharmacies 4.4.2.3.2. Drugs Stores and Retail Pharmacies 4.4.2.3.3. Online Pharmacies 4.4.3. Mexico 4.4.3.1. Mexico Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 4.4.3.1.1. Antidepressants 4.4.3.1.2. Anticonvulsant 4.4.3.1.3. Opioids 4.4.3.1.4. Capsaicin 4.4.3.1.5. Others 4.4.3.2. Mexico Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 4.4.3.2.1. Diabetic Neuropathy 4.4.3.2.2. Spinal Stenosis 4.4.3.2.3. Chemotherapy-Induced Peripheral Neuropathy 4.4.3.2.4. Others 4.4.3.3. Mexico Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.3.3.1. Hospital Pharmacies 4.4.3.3.2. Drugs Stores and Retail Pharmacies 4.4.3.3.3. Online Pharmacies 5. Europe Neuropathic Pain Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.2. Europe Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.3. Europe Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4. Europe Neuropathic Pain Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.1.2. United Kingdom Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.1.3. United Kingdom Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.2. France 5.4.2.1. France Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.2.2. France Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.2.3. France Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.3. Germany 5.4.3.1. Germany Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.3.2. Germany Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.3.3. Germany Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.4.2. Italy Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.4.3. Italy Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.5. Spain 5.4.5.1. Spain Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.5.2. Spain Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.5.3. Spain Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.6.2. Sweden Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.6.3. Sweden Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.7.2. Austria Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.7.3. Austria Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 5.4.8.2. Rest of Europe Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 5.4.8.3. Rest of Europe Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6. Asia Pacific Neuropathic Pain Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.2. Asia Pacific Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.3. Asia Pacific Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4. Asia Pacific Neuropathic Pain Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.1.2. China Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.1.3. China Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.2.2. S Korea Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.2.3. S Korea Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.3.2. Japan Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.3.3. Japan Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.4. India 6.4.4.1. India Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.4.2. India Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.4.3. India Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.5.2. Australia Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.5.3. Australia Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.6.2. Indonesia Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.6.3. Indonesia Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.7.2. Malaysia Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.7.3. Malaysia Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.8.2. Vietnam Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.8.3. Vietnam Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.9.2. Taiwan Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.9.3. Taiwan Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 6.4.10.2. Rest of Asia Pacific Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 6.4.10.3. Rest of Asia Pacific Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 7. Middle East and Africa Neuropathic Pain Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 7.2. Middle East and Africa Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 7.3. Middle East and Africa Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 7.4. Middle East and Africa Neuropathic Pain Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 7.4.1.2. South Africa Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 7.4.1.3. South Africa Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 7.4.2.2. GCC Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 7.4.2.3. GCC Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 7.4.3.2. Nigeria Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 7.4.3.3. Nigeria Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 7.4.4.2. Rest of ME&A Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 7.4.4.3. Rest of ME&A Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 8. South America Neuropathic Pain Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 8.2. South America Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 8.3. South America Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 8.4. South America Neuropathic Pain Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 8.4.1.2. Brazil Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 8.4.1.3. Brazil Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 8.4.2.2. Argentina Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 8.4.2.3. Argentina Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Neuropathic Pain Market Size and Forecast, by Drug Class (2023-2030) 8.4.3.2. Rest Of South America Neuropathic Pain Market Size and Forecast, by Indication (2023-2030) 8.4.3.3. Rest Of South America Neuropathic Pain Market Size and Forecast, by Distribution Channel (2023-2030) 9. Global Neuropathic Pain Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Neuropathic Pain Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Pfizer Inc. - New York, United States 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Eli Lilly and Company - Indianapolis, United States 10.3. Johnson & Johnson - New Brunswick, United States 10.4. Teva Pharmaceutical Industries Ltd. - Tel Aviv, Israel 10.5. Purdue Pharma - Stamford, United States 10.6. Endo Pharmaceuticals Inc. - Dublin, Ireland 10.7. AbbVie Inc. - North Chicago, United States 10.8. Mallinckrodt Pharmaceuticals - Staines-upon-Thames, United Kingdom 10.9. Biogen Inc. - Cambridge, United States 10.10. GlaxoSmithKline plc - Brentford, United Kingdom 10.11. Novartis AG - Basel, Switzerland 10.12. AstraZeneca plc - Cambridge, United Kingdom 10.13. Bayer AG - Leverkusen, Germany 10.14. Merck KGaA - Darmstadt, Germany 10.15. Boehringer Ingelheim - Ingelheim am Rhein, Germany 10.16. Sanofi - Paris, France 10.17. UCB S.A. - Brussels, Belgium 10.18. Ipsen Pharma - Paris, France 10.19. Grünenthal GmbH - Aachen, Germany 10.20. Takeda Pharmaceutical Company Limited - Tokyo, Japan 10.21. Eisai Co., Ltd. - Tokyo, Japan 10.22. Astellas Pharma Inc. - Tokyo, Japan 10.23. Otsuka Holdings Co., Ltd. - Tokyo, Japan 10.24. Mitsubishi Tanabe Pharma Corporation - Osaka, Japan 11. Key Findings 12. Industry Recommendations 13. Neuropathic Pain Market: Research Methodology 14. Terms and Glossary